FDA: PCCPs Not Enough For Post-Market Surveillance Of AI

By Cara Smith / February 22, 2024 at 2:13 PM

An FDA official told Inside TeleHealth that proposed change control plans for emerging health technologies -- like artificial intelligence and machine-learning software -- are not enough alone to ensure adequate post-market surveillance.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.